SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending following reported 700% year-over-year revenue growth, fueled by recent expanded global approvals for its cancer therapies in the EU and Saudi Arabia. The community is buzzing with anticipation of a significant short squeeze and further label expansions, highlighting the immense potential of its diverse immunotherapy platform.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending after its CagriSema weight-loss drug trial achieved 23% weight loss but missed its primary endpoint of non-inferiority compared to Eli Lilly's tirzepatide, causing a significant stock drop. The community is debating whether this market reaction is an overblown response to a minor efficacy difference, creating a buying opportunity, or if it signals a tougher competitive landscape against its rival.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is buzzing after securing FDA approval for BYSANTI, its new drug for bipolar I disorder and schizophrenia, a development the community sees as a significant re-rating catalyst due to its New Chemical Entity status and patent protection extending to 2044. This long-term exclusivity is fueling widespread speculation about potential buyout offers from major pharmaceutical companies and the stock's short squeeze potential, even as some investors eye commercial launch timelines and possible dilution.

Atomera, Inc. engages in the development, commercialization, and licensing of proprietary processes and technologies for the semiconductor industry. It developed Mears Silicon Technology, which increases performance and power efficiency in semiconductor transistors. The company was founded by Robert Mears on November 26, 2001 and is headquartered in Los Gatos, CA.

Atomera Inc

Atomera (ATOM) is trending as a recent direct stock offering at $5 sparks debate, with bulls viewing it as a strategic move to fund game-changing MST technology for AI and data centers, while bears voice skepticism over dilution given the company's pre-revenue status and historical performance.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as investors digest news of a significant stock sale filing from Trump's trust, fueling community discussions around potential dilution and the company's highly scrutinized financial viability. There is ongoing anticipation of upcoming reports and updates regarding a debated 'fusion deal' amidst concerns about its fundamental value.

Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Redwood City MD.

Arcellx Inc

Arcellx ($ACLX) is surging after Gilead Sciences ($GILD) announced its acquisition for $115 per share in cash, valuing the cancer therapy developer at up to $7.8 billion. The biotech community is enthusiastically discussing the significant premium and the potential for increased M&A activity in the oncology sector.

Domino's Pizza, Inc. engages in the management of a network of company-owned and franchise-owned pizza stores. It operates through the following segments: U.S. Stores, International Franchise, and Supply Chain. The U.S. Stores segment consists primarily of franchise operations. The International Franchise segment comprises a network of franchised stores. The Supply Chain segment manages regional dough manufacturing and food supply chain centers. The company was founded by James Monaghan and Thomas Stephen Monaghan in 1960 and is headquartered in Ann Arbor, MI.

Dominos Pizza Inc

Domino's is trending after reporting Q4 earnings with strong revenue and a dividend increase, though an EPS miss has fueled community debate over its "Hungry for MORE" strategy driving market share gains against competitive and macro pressures.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending on the heels of its latest financial results, which exceeded expectations, and significant advancements across its neuroscience pipeline, including the priority review of AXS-05 for Alzheimer's disease agitation. Investors are keenly focused on the company's strong commercial momentum and path to cash flow positivity, with numerous analyst upgrades reflecting bullish sentiment despite initial market reactions.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is surging on overwhelmingly positive Phase 2 S-OLARIS trial results for sonelokimab in axSpA, which demonstrated exceptional efficacy and potential disease-modifying effects, further bolstered by a robust financial outlook. The community is actively discussing the drug's best-in-class potential, its significant market opportunity, and a major institutional buy-in, fueling expectations for a substantial re-evaluation and potential short squeeze ahead of its Investor Day.

20/20 Biolabs, Inc. engages in development and commercialization of proteomics product line. Its products include One Test, PAULA's Test and BioCheck Suspisious Powder Testing Kit. The company was founded by Jonathan Cohen in May 2000 and is headquartered in Gaithersburg, MD.

20/20 Biolabs Inc

AIDX is trending due to extreme post-IPO volatility, experiencing significant declines as community discussion points to a potential "pump and dump" for the newly public direct lister, also facing headwinds from a sector-wide downturn in the liquid biopsy space.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Personalis (NASDAQ:PSNL) Shares Down 4.8% - Should You Sell?

Personalis (NASDAQ:PSNL) Shares Down 4.8% - Here's What Happened...

Personalis (PSNL) to Release Earnings on Thursday

Personalis (NASDAQ:PSNL) will be releasing its Q4 2025 earnings before the market opens on Thursday, February 26. (View Earnings Report at...

Personalis (NASDAQ:PSNL) Trading Up 6.2% - Time to Buy?

Personalis (NASDAQ:PSNL) Trading 6.2% Higher - Here's Why...

Personalis to Participate in the TD Cowen 46th Annual Healthcare Conference

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the TD Cowen 46th Annual Healthcare Conference on...

Personalis, Inc. (NASDAQ:PSNL) Receives Average Rating of "Moderate Buy" from Brokerages

Personalis, Inc. (NASDAQ:PSNL - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eight brokerages that are presently covering the company, MarketBeat Ratings...

Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its fourth quarter and full year 2025 financial results on Thursday...

Personalis (NASDAQ:PSNL) Price Target Raised to $13.00

BTIG Research boosted their price target on Personalis from $12.00 to $13.00 and gave the company a "buy" rating in a research note on Wednesday...

<ul class="summary-bullets"><li>The company said the decision expands coverage beyond its earlier breast cancer indication.</li><li>NeXT Personal uses whole-genome sequencing and advanced noise-suppression processes to identify tiny amounts of circulating tumor DNA (ctDNA) in a patient’s blood.&nbsp;</li><li>The Medicare decision is backed by data generated through a long-term collaboration with the TRACERx consortium.</li></ul>Personalis, Inc. (PSNL) announced on Tuesday that Medicare will now reimburse its NeXT Personal molecular residual disease (MRD) test for use in monitoring patients with early- to mid-stage non-small cell lung cancer (NSCLC).The company stated the decision expands coverage beyond its earlier breast cancer indication, giving broader access to the assay for Medicare beneficiaries.<h2 class="st-heading-2">Why Lung Cancer Coverage Matters</h2>Under the new determination, Medicare will pay for NeXT Personal when used to track cancer recurrence and residual disease in patients with Stage I through Stage III NSCLC.&nbsp;Lung cancer remains the deadliest cancer in the U.S., with hundreds of thousands of Americans diagnosed each year and a high risk of recurrence following initial treatment.Following the announcement,&nbsp;<a href="https://stocktwits.com/symbol/PSNL">Personalis’ stock</a> traded over 16% higher in Tuesday’s premarket. On Stocktwits, retail sentiment around the stock jumped to ‘bullish’ from ‘neutral’ territory the previous day amid ‘normal’ message volume levels.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_02_10_065823_png_e12653533e.webp" alt="PSNL’s Sentiment Meter and Message Volume as of 07:00 a.m. ET on Feb. 10, 2026 | Source: Stocktwits" width="936" height="103"><figcaption>PSNL’s Sentiment Meter and Message Volume as of 07:00 a.m. ET on Feb. 10, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">How The NeXt Test Works</h2>NeXT Personal uses whole-genome sequencing and advanced noise-suppression processes to identify tiny amounts of circulating tumor DNA (ctDNA) in a patient’s blood. By tracking up to about 1,800 unique tumor mutations, clinicians can detect signs of residual or returning cancer earlier than with traditional imaging.<blockquote>"For the first time, Medicare beneficiaries battling lung cancer will have access to ultrasensitive MRD testing, providing the deep insights needed to manage their care with greater confidence.”-Chris Hall, President and CEO, Personalis</blockquote>The Medicare decision is supported by data from a long-term collaboration with the TRACERx consortium, which recently published results in Cell, validating the test’s performance in lung cancer surveillance.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ai-rally-hedge-fund-mark-spitznagel-trouble-ahead/cZbUPMiR4Yk">AI Is Real, But The Rally May Not Be: Hedge Fund Veteran Mark Spitznagel Reportedly Sees Trouble Ahead</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Division of Pulmonology and Critical Care nurse practitioner Jeanne Millett, left, and pulmonologist Dr. Thomas Smith review lung cancer screening scans.

Why Personalis Stock Is Rising: Medicare Covers Lung Cancer MRD Test

Medicare will reimburse the company’s NeXT Personal molecular residual disease (MRD) test when used to monitor patients with early to mid-stage non-small cell lung cancer (NSCLC).

Equity

Medicare will reimburse the company’s NeXT Personal molecular residual disease (MRD) test when used to monitor patients with early to mid-stage non-small cell lung cancer (NSCLC).


Wellington Shields Capital Management LLC Cuts Stake in Personalis, Inc. $PSNL

Wellington Shields Capital Management LLC trimmed its stake in shares of Personalis, Inc. (NASDAQ:PSNL - Free Report) by 31.5% during the 3rd quarter, according to the company in its most recent 13F...

Wall Street Zen Upgrades Personalis (NASDAQ:PSNL) to Hold

Wall Street Zen upgraded shares of Personalis from a "sell" rating to a "hold" rating in a research note on Saturday...

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.

Personalis Inc

Tech stocks

Energy

Cash / Bonds

Crypto

What&#39;s your biggest portfolio allocation right now?

Stocktwits

What's your biggest portfolio allocation right now?

Stocktwits Polls

The unsuccessful NHS Galleri trial for early cancer detection highlights this company's differentiated focus on targeted MRD and personalized vaccines.

Discussion centers on the company's strong foundation in personalized cancer vaccines and targeted ctDNA tests for recurrence monitoring.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.29	--	--	N/A
Q3 '25	-$0.27	-$0.24	11.52%	BEAT
Q2 '25	-$0.24	-$0.23	4.17%	BEAT
Q1 '25	-$0.25	-$0.18	27.17%	BEAT
Q4 '24	-$0.28	-$0.23	18.82%	BEAT

PSNL
Personalis Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest PSNL News

PSNLPersonalis Inc